Chime Bio, flush with $190M, blueprints major biomanufacturing boost in China

Apr 5, 2021 12:23pm
Chime Biologics' second biologics site, pictured above, will lift total manufacturing capacity to 140,000 liters, the CDMO said.(PR Newswire/Chime Biologics)
After locking up a $125 million Series A in early 2020, China-based CDMO Chime Biologics has raised another $65 million to help build and kit out a second plant in Wuhan, China. 
The $190 million investment will fuel an expansion over the next five years at its site in Wuhan, taking capacity there to 140,000 liters.
The new plant will join Chime's first facility there, which is built around a modular manufacturing system from Cytiva Life Sciences. Chime counts monoclonal and bispecific antibodies, fusion and conjugated proteins, and enzymes among its manufacturing repertoire, according to the company’s website.

Related Keywords

China ,Wuxi ,Jiangsu ,Wuhan ,Hubei ,Suzhou , ,Cytiva Life Sciences ,Fidelity International ,Cytiva Life ,Wuhan East Lake High Tech ,Marketing Authorization Holder ,Fierce Pharma ,Panacea Venture ,Wuxi Bio ,Wuxi Biologics ,Cytiva ,Ge Healthcare ,Chime Biologics ,Cdmo ,Biologics ,Biologics Plant ,Drug Manufacturing ,Manufacturing Plant ,Manufacturing Expansion ,Pharma ,Manufacturing ,சீனா ,சூழோ ,நம்பகத்தன்மை சர்வதேச ,சந்தைப்படுத்தல் அங்கீகாரம் வைத்திருப்பவர் ,கடுமையான பார்மா ,சஞ்சீவி துணிகர ,கே சுகாதாரம் ,சிம்ம உயிரியல் ,கதிமோ ,உயிரியல் ,உயிரியல் ஆலை ,மருந்து உற்பத்தி ,உற்பத்தி ஆலை ,உற்பத்தி விரிவாக்கம் ,பார்மா ,உற்பத்தி ,